JP6092870B2 - メタ置換ビフェニル末梢に限局されたfaah阻害剤 - Google Patents
メタ置換ビフェニル末梢に限局されたfaah阻害剤 Download PDFInfo
- Publication number
- JP6092870B2 JP6092870B2 JP2014526261A JP2014526261A JP6092870B2 JP 6092870 B2 JP6092870 B2 JP 6092870B2 JP 2014526261 A JP2014526261 A JP 2014526261A JP 2014526261 A JP2014526261 A JP 2014526261A JP 6092870 B2 JP6092870 B2 JP 6092870B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- faah
- compound according
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/02—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525636P | 2011-08-19 | 2011-08-19 | |
| US61/525,636 | 2011-08-19 | ||
| PCT/US2012/051478 WO2013028570A2 (en) | 2011-08-19 | 2012-08-17 | Meta-substituted biphenyl peripherally restricted faah inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527532A JP2014527532A (ja) | 2014-10-16 |
| JP2014527532A5 JP2014527532A5 (OSRAM) | 2015-10-01 |
| JP6092870B2 true JP6092870B2 (ja) | 2017-03-08 |
Family
ID=47747054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526261A Active JP6092870B2 (ja) | 2011-08-19 | 2012-08-17 | メタ置換ビフェニル末梢に限局されたfaah阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9745255B2 (OSRAM) |
| EP (1) | EP2744778B1 (OSRAM) |
| JP (1) | JP6092870B2 (OSRAM) |
| KR (1) | KR102079404B1 (OSRAM) |
| CN (1) | CN104203906B (OSRAM) |
| AU (1) | AU2012299060B2 (OSRAM) |
| BR (1) | BR112014003886B1 (OSRAM) |
| CA (1) | CA2844812C (OSRAM) |
| DK (1) | DK2744778T3 (OSRAM) |
| ES (1) | ES2708723T3 (OSRAM) |
| MX (1) | MX354772B (OSRAM) |
| WO (1) | WO2013028570A2 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006001567A1 (en) * | 2004-06-24 | 2006-01-05 | Bioleaders Corporation | Poly-gamma-glutamic acid-vitamin complex and use thereof |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2708723T3 (es) | 2011-08-19 | 2019-04-10 | Univ California | Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo |
| WO2014023325A1 (en) * | 2012-08-06 | 2014-02-13 | Fondazione Istituto Italiano Di Tecnologia | Multitarget faah and cox inhibitors and therapeutical uses thereof |
| ES2908240T3 (es) | 2014-04-07 | 2022-04-28 | Univ California | Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos |
| CN108348468A (zh) * | 2015-08-11 | 2018-07-31 | Eyesiu医疗股份有限公司 | 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒 |
| WO2017197240A1 (en) * | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| MY172113A (en) | 2017-07-05 | 2019-11-14 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US10702487B2 (en) | 2017-08-19 | 2020-07-07 | Frimline Private Limited | Pharmaceutical composition for prevention of diet induced obesity |
| SG10201807034XA (en) | 2017-09-05 | 2019-04-29 | Frimline Private Ltd | A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease |
| GB201802326D0 (en) | 2018-02-13 | 2018-03-28 | Ucl Business Plc | Gene therapy |
| US12023332B2 (en) | 2018-03-05 | 2024-07-02 | Wylder Nation Foundation | Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin |
| AU2020206722A1 (en) * | 2019-01-10 | 2021-07-29 | Travecta Therapeutics Pte. Ltd. | Anandamide compounds |
| US20230313196A1 (en) * | 2020-07-23 | 2023-10-05 | John Mansell | Compositions and methods for treating pain and anxiety disorders |
| CN120965462A (zh) * | 2025-10-17 | 2025-11-18 | 四川奥邦古得药业有限公司 | 用于生产3,5-二醚戊苯的方法及其在制备3,5-二羟基戊苯中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4325889A (en) | 1978-08-04 | 1982-04-20 | Bayer Aktiengesellschaft | Process for the preparation of 1-amino-8-naphthol-3,6-disulphonic acid (H-acid) |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4511503A (en) | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| US5559410A (en) | 1992-12-17 | 1996-09-24 | Valeo Systemes D'essuyage | Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield |
| US5576220A (en) | 1993-02-19 | 1996-11-19 | Arris Pharmaceutical Corporation | Thin film HPMP matrix systems and methods for constructing and displaying ligands |
| US6271015B1 (en) | 1995-06-12 | 2001-08-07 | The Scripps Research Institute | Fatty-acid amide hydrolase |
| CA2206192A1 (en) | 1996-06-13 | 1997-12-13 | F. Hoffmann-La Roche Ag | Modulation of lc132 (opioid-like) receptor function |
| AU731672B2 (en) | 1996-12-02 | 2001-04-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating bipolar disorders |
| GB9701453D0 (en) | 1997-01-24 | 1997-03-12 | Leo Pharm Prod Ltd | Aminobenzophenones |
| FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| TW492882B (en) | 1997-11-28 | 2002-07-01 | Caleb Pharmaceuticals Inc | Cholinergic antagonist plaster composition |
| NZ506465A (en) | 1998-02-26 | 2003-08-29 | Akzo Nobel Nv | Derivatives of azetidine and pyrrolidine |
| CA2330681C (en) | 1998-05-29 | 2008-08-26 | Andrea Giuffrida | Control of pain with endogenous cannabinoids |
| US7897598B2 (en) | 1998-06-09 | 2011-03-01 | Alexandros Makriyannis | Inhibitors of the anandamide transporter |
| US20030134894A1 (en) | 1999-04-07 | 2003-07-17 | Daniele Piomelli | Methods of treating mental diseases, inflammation and pain |
| US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
| AU2003237882B2 (en) | 2002-05-16 | 2010-04-08 | Sunovion Pharmaceuticals Inc. | Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| FR2842808B1 (fr) | 2002-07-25 | 2004-09-10 | Sod Conseils Rech Applic | Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques |
| AU2003279877B2 (en) * | 2002-10-07 | 2010-05-20 | The Regents Of The University Of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| FR2850377B1 (fr) | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| US9316633B2 (en) | 2006-11-16 | 2016-04-19 | The Regents Of The University Of California | Methods for identifying inhibitors of solute transporters |
| US20080119549A1 (en) * | 2006-11-20 | 2008-05-22 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| TW200948805A (en) | 2008-03-07 | 2009-12-01 | Sigma Tau Ind Farmaceuti | Enol carbamate derivatives as modulators of fatty acid amide hydrolase |
| PT2488486T (pt) | 2009-10-13 | 2019-11-05 | Ligand Pharm Inc | Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos |
| WO2012015704A2 (en) * | 2010-07-28 | 2012-02-02 | The Regents Of The University Of California | Peripherally restricted faah inhibitors |
| WO2012167133A2 (en) | 2011-06-01 | 2012-12-06 | The Regents Of The University Of California | Inhibitors of anandamide transport and their therapeutic uses |
| ES2708723T3 (es) | 2011-08-19 | 2019-04-10 | Univ California | Inhibidores de FAAH restringidos de forma periférica sustituidos en posición meta por bifenilo |
| ES2908240T3 (es) | 2014-04-07 | 2022-04-28 | Univ California | Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos |
-
2012
- 2012-08-17 ES ES12826376T patent/ES2708723T3/es active Active
- 2012-08-17 EP EP12826376.1A patent/EP2744778B1/en active Active
- 2012-08-17 DK DK12826376.1T patent/DK2744778T3/en active
- 2012-08-17 CA CA2844812A patent/CA2844812C/en active Active
- 2012-08-17 BR BR112014003886-4A patent/BR112014003886B1/pt active IP Right Grant
- 2012-08-17 AU AU2012299060A patent/AU2012299060B2/en active Active
- 2012-08-17 WO PCT/US2012/051478 patent/WO2013028570A2/en not_active Ceased
- 2012-08-17 MX MX2014001966A patent/MX354772B/es active IP Right Grant
- 2012-08-17 CN CN201280051448.5A patent/CN104203906B/zh active Active
- 2012-08-17 KR KR1020147007303A patent/KR102079404B1/ko active Active
- 2012-08-17 JP JP2014526261A patent/JP6092870B2/ja active Active
-
2014
- 2014-02-18 US US14/183,073 patent/US9745255B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006001567A1 (en) * | 2004-06-24 | 2006-01-05 | Bioleaders Corporation | Poly-gamma-glutamic acid-vitamin complex and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| MX354772B (es) | 2018-03-21 |
| EP2744778B1 (en) | 2019-01-16 |
| BR112014003886A8 (pt) | 2018-01-23 |
| HK1198644A1 (en) | 2015-05-22 |
| WO2013028570A3 (en) | 2013-04-18 |
| BR112014003886A2 (pt) | 2017-03-21 |
| AU2012299060B2 (en) | 2017-06-01 |
| CN104203906B (zh) | 2018-03-13 |
| DK2744778T3 (en) | 2019-03-04 |
| EP2744778A2 (en) | 2014-06-25 |
| US9745255B2 (en) | 2017-08-29 |
| WO2013028570A2 (en) | 2013-02-28 |
| CA2844812C (en) | 2019-10-22 |
| ES2708723T3 (es) | 2019-04-10 |
| JP2014527532A (ja) | 2014-10-16 |
| MX2014001966A (es) | 2015-04-08 |
| KR20150100485A (ko) | 2015-09-02 |
| EP2744778A4 (en) | 2015-04-08 |
| KR102079404B1 (ko) | 2020-02-19 |
| NZ622480A (en) | 2016-05-27 |
| CN104203906A (zh) | 2014-12-10 |
| CA2844812A1 (en) | 2013-02-28 |
| AU2012299060A1 (en) | 2014-04-03 |
| US20140288170A1 (en) | 2014-09-25 |
| BR112014003886B1 (pt) | 2022-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6092870B2 (ja) | メタ置換ビフェニル末梢に限局されたfaah阻害剤 | |
| CA2843265C (en) | Peripherally restricted faah inhibitors | |
| JP6989505B2 (ja) | Malt1阻害剤およびその使用 | |
| KR20050088992A (ko) | 아난드아미드 가수분해 차단을 통한 불안감의 조절 | |
| EP2745876A1 (en) | Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives | |
| US20160235707A1 (en) | Disubstituted beta-lactones as inhibitors of n-acylethanolamine acid amidase (naaa) | |
| EP3119768B1 (en) | 3,4-bromo or -sulfonate substituted 1h-pyrrole-2,5-dione derivatives as type iii deiodinase (dio3) inhibitors for treating depressions and cancer | |
| RS53747B1 (sr) | Jedinjenja fenantrenona, kompozicije i metode | |
| EA022158B1 (ru) | Модуляторы активности гидролазы амидов жирных кислот | |
| WO2016173274A1 (zh) | 芳香族法尼基类化合物及其应用 | |
| HK1198644B (en) | Meta-substituted biphenyl peripherally restricted faah inhibitors | |
| Elumalai et al. | Development of potent cholinesterase inhibitors based on a marine pharmacophore | |
| Francavilla et al. | Design, Synthesis, and Biological Evaluation of Novel Heteroaryl, Squaramide, and Indolcarboxamide Derivatives as Formyl Peptide Receptor 2 Agonists to Target Neuroinflammation | |
| NZ622480B2 (en) | Meta-substituted biphenyl peripherally restricted faah inhibitors | |
| JP2008533122A (ja) | 新規なチロシン誘導体 | |
| WO2024044751A2 (en) | Peroxiredoxin 3 inhibitors and methods of use for treating cancer | |
| Singh Grewal et al. | Synthesis, Docking and Evaluation of Phenylacetic Acid and Trifluoro-methylphenyl Substituted Benzamide Derivatives as Potential PPARδ Agonists | |
| CN120365267A (zh) | 一种螺环和双杂环萘磺酰胺类衍生物及其应用 | |
| US20180207123A1 (en) | Ceramide derivatives as anticancer agents | |
| KR20080075922A (ko) | 칼슘 채널 차단제로서의 디벤젠 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150814 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150814 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160405 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160630 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161005 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6092870 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |